

Riccardo Saccardi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5154549/publications.pdf>

Version: 2024-02-01

111
papers

6,231
citations

61857

43
h-index

71532

76
g-index

113
all docs

113
docs citations

113
times ranked

6905
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of GVHD on outcomes after adult single cord blood transplantation in European and Japanese populations. <i>Bone Marrow Transplantation</i> , 2022, 57, 57-64.	1.3	8
2	AIDS patient with severe T cell depletion achieved control but not clearance of SARS-CoV-2 infection. <i>European Journal of Immunology</i> , 2022, 52, 352-355.	1.6	16
3	Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 399-406.	1.3	9
4	Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 416-422.	1.3	11
5	Autologous haematopoietic stem cell transplantation versus low-dose immunosuppression in secondary progressive multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 1708-1718.	1.7	14
6	Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2022, 13, 820256.	1.1	6
7	Benchmarking survival outcomes: A funnel plot for survival data. <i>Statistical Methods in Medical Research</i> , 2022, 31, 1171-1183.	0.7	5
8	Haematopoietic stem cell transplantation for severe autoimmune diseases in children: A review of current literature, registry activity and future directions on behalf of the autoimmune diseases and paediatric diseases working parties of the European Society for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2022, 198, 24-45.	1.2	3
9	A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis. <i>Journal of Neurology</i> , 2022, 269, 5337-5346.	1.8	2
10	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	1.3	1
11	Prevalence of disability improvement as a potential outcome for multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2021, 27, 706-711.	1.4	6
12	Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 61-70.	1.4	16
13	Long-term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, .	1.5	36
14	New autoimmune diseases after autologous hematopoietic stem cell transplantation for multiple sclerosis. <i>Bone Marrow Transplantation</i> , 2021, 56, 1509-1517.	1.3	14
15	Hematopoietic stem cell transplantation for autoimmune diseases in the time of COVID-19: EBMT guidelines and recommendations. <i>Bone Marrow Transplantation</i> , 2021, 56, 1493-1508.	1.3	27
16	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation. <i>Haematologica</i> , 2020, 105, e186-e189.	1.7	12
17	Autologous haematopoietic stem cell transplantation and other cellular therapy in multiple sclerosis and immune-mediated neurological diseases: updated guidelines and recommendations from the EBMT Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and ISCT (IACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 283-306.	1.3	128
18	Prognostic factors for adult single cord blood transplantation among European and Japanese populations: the Eurocord/ALWP-EBMT and JSHCT/JDCHCT collaborative study. <i>Leukemia</i> , 2020, 34, 128-137.	3.3	36

#	ARTICLE	IF	CITATIONS
19	Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the Infectious Diseases Working Party of EBMT. <i>Journal of Neurology</i> , 2020, 267, 430-439.	1.8	13
20	Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2020, 55, 681-694.	1.3	39
21	Multi-laboratory assay for harmonization of enumeration of viable CD34+ and CD45+ cells in frozen cord blood units. <i>Cytotherapy</i> , 2020, 22, 44-51.	0.3	12
22	Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Haematologica</i> , 2020, 105, 297-316.	1.7	230
23	Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 138-144.	1.1	5
24	Reduced-Intensity versus Myeloablative Conditioning in Cord Blood Transplantation for Acute Myeloid Leukemia (40-60 years) across Highly Mismatched HLA Barriers – On Behalf of Eurocord and the Cellular Therapy & Immunobiology Working Party (CTIWP) of EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2098-2104.	2.0	9
25	Rehabilitation Before and After Autologous Haematopoietic Stem Cell Transplantation (AHSCT) for Patients With Multiple Sclerosis (MS): Consensus Guidelines and Recommendations for Best Clinical Practice on Behalf of the Autoimmune Diseases Working Party, Nurses Group, and Patient Advocacy Committee of the European Society for Blood and Marrow Transplantation (EBMT). <i>Frontiers in Neurology</i> , 2020, 11, 5561-41.	1.1	8
26	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. <i>Bone Marrow Transplantation</i> , 2020, 55, 2244-2253.	1.3	6
27	Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). <i>Frontiers in Immunology</i> , 2020, 11, 524.	2.2	100
28	The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies. <i>Frontiers in Immunology</i> , 2020, 11, 559.	2.2	25
29	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
30	Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience. <i>International Urology and Nephrology</i> , 2019, 51, 1715-1720.	0.6	11
31	Allogeneic HSCT for Autoimmune Diseases: A Retrospective Study From the EBMT ADWP, IEWP, and PDWP Working Parties. <i>Frontiers in Immunology</i> , 2019, 10, 1570.	2.2	48
32	A non-traditional approach to cryopreservation by ultra-rapid cooling for human mesenchymal stem cells. <i>PLoS ONE</i> , 2019, 14, e0220055.	1.1	5
33	General information for patients and carers considering haematopoietic stem cell transplantation (HSCT) for severe autoimmune diseases (ADs): A position statement from the EBMT Autoimmune Diseases Working Party (ADWP), the EBMT Nurses Group, the EBMT Patient, Family and Donor Committee and the Joint Accreditation Committee of ISCT and EBMT (JACIE). <i>Bone Marrow Transplantation</i> , 2019, 54, 933-942.	1.3	25
34	Individualized prediction of leukemia-free survival after autologous stem cell transplantation in acute myeloid leukemia. <i>Cancer</i> , 2019, 125, 3566-3573.	2.0	17
35	Autologous haematopoietic stem cell therapy for multiple sclerosis: a review for supportive care clinicians on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation. <i>Current Opinion in Supportive and Palliative Care</i> , 2019, 13, 394-401.	0.5	10
36	JACIE Accreditation of HSCT Programs. , 2019, , 35-40.		11

#	ARTICLE	IF	CITATIONS
37	Autologous Haematopoietic Stem Cell Transplantation (AHSCT) in Severe Crohn's Disease: A Review on Behalf of ECCO and EBMT. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 476-488.	0.6	43
38	Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia. The SCelta Trial. <i>Circulation Journal</i> , 2018, 82, 1688-1698.	0.7	23
39	The effects of Exendin-4 on bone marrow-derived mesenchymal cells. <i>Endocrine</i> , 2018, 60, 423-434.	1.1	9
40	Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 245-255.	1.4	42
41	Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 110.	6.9	41
42	Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19+ tumors. <i>Cytotherapy</i> , 2018, 20, 1077-1088.	0.3	8
43	NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs. <i>Multiple Sclerosis Journal</i> , 2017, 23, 201-204.	1.4	72
44	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017, 74, 459.	4.5	199
45	Impact of CTLA4 genotype and other immune response gene polymorphisms on outcomes after single umbilical cord blood transplantation. <i>Blood</i> , 2017, 129, 525-532.	0.6	7
46	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2017, 88, 2115-2122.	1.5	134
47	Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis. <i>Nature Reviews Neurology</i> , 2017, 13, 391-405.	4.9	207
48	Autologous stem-cell transplantation in treatment-refractory Crohn's disease: an analysis of pooled data from the ASTIC trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 399-406.	3.7	70
49	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
50	Evolution, trends, outcomes, and economics of hematopoietic stem cell transplantation in severe autoimmune diseases. <i>Blood Advances</i> , 2017, 1, 2742-2755.	2.5	151
51	Fully automated, clinical-grade bone marrow processing: a single-centre experience. <i>Blood Transfusion</i> , 2017, 15, 577-584.	0.3	8
52	Local injection of bone marrow progenitor cells for the treatment of anal sphincter injury: in-vitro expanded versus minimally-manipulated cells. <i>Stem Cell Research and Therapy</i> , 2016, 7, 85.	2.4	17
53	Impact of cord blood banking technologies on clinical outcome: a Eurocord/Cord Blood Committee (CTIWP), European Society for Blood and Marrow Transplantation and NetCord retrospective analysis. <i>Transfusion</i> , 2016, 56, 2021-2029.	0.8	17
54	Donor-Specific Anti-HLA Antibodies in Huntington's Disease Recipients of Human Fetal Striatal Grafts. <i>Cell Transplantation</i> , 2015, 24, 811-817.	1.2	12

#	ARTICLE	IF	CITATIONS
55	Autologous hematopoietic stem cell transplantation in multiple sclerosis. <i>Neurology</i> , 2015, 84, 981-988.	1.5	201
56	Autologous Hematopoietic Stem Cell Transplantation for Refractory Crohn Disease. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2524.	3.8	136
57	<scp>MSCs</scp> seeded on bioengineered scaffolds improve skin wound healing in rats. <i>Wound Repair and Regeneration</i> , 2015, 23, 115-123.	1.5	60
58	Autologous hematopoietic stem cell transplantation in neuromyelitis optica: A registry study of the EBMT Autoimmune Diseases Working Party. <i>Multiple Sclerosis Journal</i> , 2015, 21, 189-197.	1.4	56
59	Low intensity lympho-ablative regimen followed by autologous hematopoietic stem cell transplantation in severe forms of multiple sclerosis: A MRI-based clinical study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1423-1430.	1.4	45
60	Fetal striatal grafting slows motor and cognitive decline of Huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 974-981.	0.9	34
61	Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. <i>Haematologica</i> , 2014, 99, 1509-1515.	1.7	48
62	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2490.	3.8	566
63	Increased CXCL10 expression in MS MSCs and monocytes is unaffected by AHSCT. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 650-658.	1.7	8
64	Flow Cytometry Assessment of CD34+ Viability in Thawed Cord Blood Units: A Multi-Center Eurocord and Netcord Study. <i>Blood</i> , 2014, 124, 851-851.	0.6	5
65	Autologous Hematopoietic Stem Cell Transplantation as a Treatment Option for Aggressive Multiple Sclerosis. <i>Current Treatment Options in Neurology</i> , 2013, 15, 270-280.	0.7	26
66	Long-Term Outcomes of Hematopoietic Stem Cell Transplantation for Severe Treatment-Resistant Autoimmune Cytopenia in Children. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 666-669.	2.0	17
67	Immunohistochemistry analysis of bone marrow biopsies in multiple sclerosis patients undergoing autologous haematopoietic stem cells transplantation. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, 1044-1048.	0.6	4
68	HCT for Nonmalignant Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S6-S9.	2.0	4
69	The Assessment of Parameters Affecting the Quality of Cord Blood by the Appliance of the Annexin V Staining Method and Correlation with CFU Assays. <i>Stem Cells International</i> , 2013, 2013, 1-10.	1.2	23
70	Evidence for reduced angiogenesis in bone marrow in SSc: immunohistochemistry and multiparametric computerized imaging analysis. <i>Rheumatology</i> , 2012, 51, 1042-1048.	0.9	14
71	Type 2 diabetes mellitus impairs the maturation of endothelial progenitor cells and increases the number of circulating endothelial cells in peripheral blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 856-864.	1.1	48
72	Dermal matrix scaffold engineered with adult mesenchymal stem cells and platelet-rich plasma as a potential tool for tissue repair and regeneration. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2012, 6, 125-134.	1.3	29

#	ARTICLE	IF	CITATIONS
73	Bone Marrow Mesenchymal Stromal Cells Stimulate Skeletal Myoblast Proliferation through the Paracrine Release of VEGF. <i>PLoS ONE</i> , 2012, 7, e37512.	1.1	93
74	Neuronal Differentiation of Human Mesenchymal Stromal Cells Increases their Resistance to A β 242 Aggregate Toxicity. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 651-664.	1.2	9
75	Human mesenchymal stromal cells preserve their stem features better when cultured in the Dulbecco's modified Eagle medium. <i>Cytotherapy</i> , 2011, 13, 539-548.	0.3	14
76	Mesenchymal stromal cells affect cardiomyocyte growth through juxtacrine Notch-1/Jagged-1 signaling and paracrine mechanisms: Clues for cardiac regeneration. <i>Journal of Molecular and Cellular Cardiology</i> , 2011, 51, 399-408.	0.9	70
77	Dendritic cells with lymphocyte-stimulating activity differentiate from human CD133 positive precursors. <i>Blood</i> , 2011, 117, 3983-3995.	0.6	11
78	Endothelial progenitor cell-dependent angiogenesis requires localization of the full-length form of uPAR in caveolae. <i>Blood</i> , 2011, 118, 3743-3755.	0.6	70
79	Bone marrow-derived mesenchymal stem cells from early diffuse systemic sclerosis exhibit a paracrine machinery and stimulate angiogenesis in vitro. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2011-2021.	0.5	75
80	Current state and future directions of autologous hematopoietic stem cell transplantation in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2071-2074.	0.5	58
81	Inhibition of Immune Synapse by Altered Dendritic Cell Actin Distribution: A New Pathway of Mesenchymal Stem Cell Immune Regulation. <i>Journal of Immunology</i> , 2010, 185, 5102-5110.	0.4	78
82	High recovery of mesenchymal progenitor cells with non-density gradient separation of human bone marrow. <i>Cytotherapy</i> , 2010, 12, 579-586.	0.3	17
83	Mesenchymal Stem Cells Prevent Acute Rejection and Prolong Graft Function in Pancreatic Islet Transplantation. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 435-446.	2.4	64
84	Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. <i>Haematologica</i> , 2010, 95, 284-292.	1.7	321
85	Hematopoietic Stem Cell Transplantation for Multiple Sclerosis: Collaboration of the CIBMTR and EBMT to Facilitate International Clinical Studies. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1076-1083.	2.0	46
86	Human striatal neuroblasts develop and build a striatal-like structure into the brain of Huntington's disease patients after transplantation. <i>Experimental Neurology</i> , 2010, 222, 30-41.	2.0	74
87	Autologous Mesenchymal Stem Cells Foster Revascularization of Ischemic Limbs in Systemic Sclerosis. <i>Annals of Internal Medicine</i> , 2010, 153, 650.	2.0	100
88	Increase in FOXP3+ Regulatory T Cells in GVHD Skin Biopsies Is Associated with Lower Disease Severity and Treatment Response. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 938-947.	2.0	43
89	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. <i>Transplantation</i> , 2009, 88, 614-619.	0.5	64
90	Stem Cell Transplantation Supports the Repair of Injured Olfactory Neuroepithelium After Permanent Lesion. , 2009, , 283-297.		4

#	ARTICLE	IF	CITATIONS
91	Treatment of Experimental Injury of Anal Sphincters with Primary Surgical Repair and Injection of Bone Marrow-Derived Mesenchymal Stem Cells. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 411-420.	0.7	86
92	Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model. <i>Archives of Dermatological Research</i> , 2008, 300, 115-124.	1.1	91
93	Autologous haematopoietic stem-cell transplantation in multiple sclerosis. <i>Lancet Neurology</i> , The, 2008, 7, 626-636.	4.9	197
94	Differences in mesenchymal stem cell cytokine profiles between MS patients and healthy donors: Implication for assessment of disease activity and treatment. <i>Journal of Neuroimmunology</i> , 2008, 199, 142-150.	1.1	71
95	Development of human striatal anlagen after transplantation in a patient with Huntington's disease. <i>Experimental Neurology</i> , 2008, 213, 241-244.	2.0	38
96	Concluding remarks. <i>Autoimmunity</i> , 2008, 41, 686-690.	1.2	3
97	Induction of CD83+CD14+Nondendritic Antigen-Presenting Cells by Exposure of Monocytes to IFN- γ . <i>Journal of Immunology</i> , 2008, 181, 2999-3008.	0.4	29
98	Haematopoietic stem cell transplantation for autoimmune disorders. <i>Current Opinion in Hematology</i> , 2008, 15, 594-600.	1.2	16
99	Cochlear Repair by Transplantation of Human Cord Blood CD133+ Cells to Nod-Scid Mice Made Deaf with Kanamycin and Noise. <i>Cell Transplantation</i> , 2008, 17, 665-678.	1.2	49
100	Prolonged human/sheep cellular chimerism following transplantation of human hemopoietic stem cells into the ewe celomic cavity. <i>International Journal of Developmental Biology</i> , 2008, 52, 365-370.	0.3	6
101	ATP Modulates Cell Proliferation and Elicits Two Different Electrophysiological Responses in Human Mesenchymal Stem Cells. <i>Stem Cells</i> , 2007, 25, 1840-1849.	1.4	76
102	Neuronal differentiation of human mesenchymal stem cells: Changes in the expression of the Alzheimer's disease-related gene seladin-1. <i>Experimental Cell Research</i> , 2006, 312, 2592-2604.	1.2	60
103	Haematopoietic stem cell transplantation for vasculitis including Behcet's disease and polycondritis: a retrospective analysis of patients recorded in the European Bone Marrow Transplantation and European League Against Rheumatism databases and a review of the literature. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 202-207.	0.5	85
104	Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. <i>Blood</i> , 2005, 105, 2601-2607.	0.6	147
105	Interaction between Human NK Cells and Bone Marrow Stromal Cells Induces NK Cell Triggering: Role of NKp30 and NKG2D Receptors. <i>Journal of Immunology</i> , 2005, 175, 6352-6360.	0.4	157
106	Feasibility of Allogeneic Hematopoietic Stem Cell Transplantation for Autoimmune Disease: Position Statement from a National Institute of Allergy and Infectious Diseases and National Cancer Institute-sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 862-870.	2.0	56
107	Autologous stem cell transplantation for systemic lupus erythematosus. <i>Lupus</i> , 2004, 13, 168-176.	0.8	169
108	Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA. <i>British Journal of Haematology</i> , 1998, 103, 610-617.	1.2	54

#	ARTICLE	IF	CITATIONS
109	In vitro chemosensitivity testing of leukemic cells: Development of a semiautomated colorimetric assay. <i>Hematological Oncology</i> , 1989, 7, 243-253.	0.8	23
110	In vitro chemosensitivity testing of leukemic cells: Prediction of response to chemotherapy in patients with acute non-lymphocytic leukemia. <i>Hematological Oncology</i> , 1989, 7, 287-293.	0.8	39
111	Potential role of interleukin-1 as the trigger for diffuse intravascular coagulation in acute nonlymphoblastic leukemia. <i>American Journal of Medicine</i> , 1988, 84, 240-250.	0.6	87